Lantheus Medical Imaging of North Billerica, MA, has finalized an arrangement with the Australian Nuclear Science and Technology Organisation (ANSTO) to receive molybdenum-99 (Mo-99) produced from low-enriched uranium (LEU) targets in ANSTO's new OPAL reactor.
Lantheus soon will receive a supply of Mo-99 at regular intervals from ANSTO for use in its TechneLite generator line that is currently distributed to the U.S. and Canadian markets.
ANSTO has secured regulatory approval from the Therapeutic Goods Administration in Australia to use the LEU Mo-99 in a technetium-99m (Tc-99m) generator. The LEU-derived Mo-99 from ANSTO has been tested and validated by Lantheus for use in its TechneLite generator line to ensure the consistency and reliability that are the hallmarks of the TechneLite brand.
In the meantime, Lantheus Medical Imaging and ANSTO are working with the U.S. Food and Drug Administration (FDA) and Health Canada to achieve the necessary LEU Mo-99 approvals for the U.S. and Canadian markets.
Related Reading
Lantheus begins testing new PET agent, September 17, 2009
Lantheus signs Australian moly deal, June 15, 2009
PETNet signs supply deal with Lantheus, June 11, 2009
Lantheus completes Definity study enrollment, May 28, 2009
Lantheus signs Mo-99 supply deal, May 20, 2009
Copyright © 2009 AuntMinnie.com
